ライフサイエンスコーパス: carbidopa

1 mask adrenal pheochromocytoma, is blocked by carbidopa.

2 PET with oral preadministration of 200 mg of carbidopa.

3 r tracer uptake by the tumors is enhanced by carbidopa.

4 ated empirically with levodopa combined with carbidopa.

5 PA in the presence of the co-drug compound L-carbidopa.

6 n humans after oral pretreatment with 100 mg carbidopa.

7 s altered significantly by pretreatment with carbidopa.

8 degeneration, and responsiveness to levodopa-carbidopa.

9 ipheral L-amino acid decarboxylase inhibitor carbidopa along with L-DOPA (C/l-DOPA).

10 Whether carbidopa also improves (18)F-DOPA PET of adrenal pheoch

11 me involved in NE cell GABA metabolism, (ii) carbidopa, an inhibitor of dopa decarboxylase which func

12 rs, especially with the preadministration of carbidopa, an inhibitor of DOPA decarboxylase.

13 ust be present at the aromatic ring of the l-carbidopa analogues and show that the presence of fluori

14 The pharmacologic inhibitors carbidopa and tetrabenazine also revealed differential e

15 Pyrocatechol, carbidopa, and isoproterenol were similarly strong induc

16 sonism responsive to treatment with levodopa-carbidopa, and nine with central neurodegeneration unres

17 ted twice daily with levodopa (15 mg/kg with carbidopa by oral gavage) for two weeks developed choreo

18 s for the determination of levodopa (LD) and carbidopa (CD) was described.

19 Compared with baseline, carbidopa detected additional lesions in 3 (27%) of 11 p

20 ults, pretreatment with the AADC inhibitor S-carbidopa did not affect the (18)F-l-FEHTP PET results.

21 tment of MPTP-treated marmosets with L-DOPA/ carbidopa did not alter the levels of specific [3H]7-OH-

22 Carbidopa did not influence in vitro (18)F-FDOPA accumul

23 Incubation of RIN-m5F cells with 80 muM carbidopa did not significantly affect the cellular accu

24 allocated to immediate-release oral levodopa-carbidopa (difference -1.91 h [95% CI -3.05 to -0.76]; p

25 Carbidopa (DOPA decarboxylase inhibitor) blunted all eff

26 en at the mid-Sinemet (250 mg levodopa-25 mg carbidopa) dose level.

27 Carbidopa enhances the sensitivity of (18)F-DOPA PET for

28 cated to the immediate-release oral levodopa-carbidopa group (seven [21%] serious), mainly associated

29 dard and megadose corticosteroids, levodopa, carbidopa, hyperbaric oxygen, and neuroprotective agents

30 y included oral levodopa plus benserazide or carbidopa in a regimen that had been stable for 4 weeks

31 Carbidopa increased the mean (+/-SD) peak standardized u

32 ed to assess efficacy and safety of levodopa-carbidopa intestinal gel delivered continuously through

33 5) for 35 patients allocated to the levodopa-carbidopa intestinal gel group compared with a decrease

34 5%) of 37 patients allocated to the levodopa-carbidopa intestinal gel group had adverse events (five

35 placebo intestinal gel infusion or levodopa-carbidopa intestinal gel infusion plus oral placebo.

36 ET false-negative results in the presence of carbidopa is a concern.

37 ossibly lead to DDC inhibitors better than l-carbidopa itself.

38 dulation by systemic injection of L-DOPA and Carbidopa (LDC) or by local application of DA in V1 and

39 s treated double-blind with extended-release carbidopa-levodopa (mean 3.6 doses per day [SD 0.7]) had

40 treated double-blind with immediate-release carbidopa-levodopa (mean 5.0 doses per day [1.2]).

41 opa and 29.79% (15.81) for immediate-release carbidopa-levodopa (mean difference -5.97, 95% CI -9.05

42 were 23.82% (SD 14.91) for extended-release carbidopa-levodopa and 29.79% (15.81) for immediate-rele

43 inson's disease who were assigned to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 7

44 went 3 weeks of open-label immediate-release carbidopa-levodopa dose adjustment followed by 6 weeks o

45 ed by 6 weeks of open-label extended-release carbidopa-levodopa dose conversion.

46 release formulation versus immediate-release carbidopa-levodopa in patients with Parkinson's disease

47 Extended-release carbidopa-levodopa might be a useful treatment for patie

48 t with extended-release or immediate-release carbidopa-levodopa plus matched placebos.

49 Extended-release carbidopa-levodopa reduced daily off-time by, on average

50 ] of 201 patients allocated extended-release carbidopa-levodopa vs two [1%] of 192 patients allocated

51 of 192 patients allocated immediate-release carbidopa-levodopa), nausea (six [3%] vs three [2%]), an

52 During dose conversion with extended-release carbidopa-levodopa, 23 (5%) of 450 patients withdrew bec

53 al, extended-release, capsule formulation of carbidopa-levodopa.

54 6; p<0.0001) compared with immediate-release carbidopa-levodopa.

55 luding a new extended release formulation of carbidopa/levodopa (IPX066), safinamide which inhibits M

56 s per day with levodopa placebo (n = 42), or carbidopa/levodopa, 25/100 mg 3 times per day with prami

57 hanged little in the past decade and include carbidopa/levodopa, dopamine agonists, and monoamine oxi

58 ement in motor function after treatment with carbidopa/levodopa.

59 ncrease did not predict clinical response to carbidopa/levodopa.

60 and 66.7% (regions) for (18)F-DOPA PET plus carbidopa (neither is statistically significant vs. base

61 patients benefit dramatically from levodopa/carbidopa, often with further improvement with the addit

62 equently, we aimed to evaluate the effect of carbidopa on (18)F-FDOPA uptake in insulinoma beta-cells

63 disease severity were administered 50 mg of carbidopa orally followed in 1 hour by an intravenous bo

64 2 vs. CT/MRI), and 57 by (18)F-DOPA PET plus carbidopa (P = 0.0075 vs. CT/MRI, not statistically sign

65 eatment with immediate-release oral levodopa-carbidopa plus placebo intestinal gel infusion or levodo

66 Regardless of carbidopa premedication, the xenografts were characteriz

67 tabolism of (18)F-DOPA-H and (18)F-DOPA-L in carbidopa-pretreated mice.

68 Experiments were conducted with and without carbidopa pretreatment.

69 Patient premedication with carbidopa seems to improve the accuracy of 6-(18)F-fluor

70 nd responsiveness to treatment with levodopa-carbidopa (Sinemet).

71 tion unresponsive to treatment with levodopa-carbidopa (the Shy-Drager syndrome).

72 Insulinoma xenografts in carbidopa-treated mice showed significantly higher (18)F

73 ely diminished circling response when l-DOPA-carbidopa was repeatedly administered at 120 min interva

74 ne-proton exchangers VMAT1 and VMAT2, and by carbidopa, which inhibits aromatic L-amino acid decarbox

75 Oral administration of carbidopa, which inhibits L-AADC outside the blood-brain

76 are precursors of fluorinated analogues of l-carbidopa, which is known to inhibit DOPA decarboxylase

77 Continuous delivery of levodopa-carbidopa with an intestinal gel offers a promising opti